Vitamin E administration at the onset of fever prevents renal scarring in acute pyelonephritis.
We evaluated the protective effects of antioxidant at the onset of fever on renal damage in a rat model of acute pyelonephritis. Twenty rats were allocated to four groups. In groups 1 to 3, the animals were given direct inoculation of Escherichia coli into the right kidney, and group four served as control. All rats in groups 1 to 3 were given once-daily intraperitoneal injections of ceftriaxon for five consecutive days, beginning on the third day after inoculation. The animals' body temperatures were monitored; as soon as body temperature reaches 38 degrees C, the rats in group 2 were given allopurinol co-treatment, whereas, in group 3, vitamin E co-treatment was started at fever onset. Both kidneys were excised 6 weeks later, for the evaluation of histopathologic changes, apoptotic damage, and concentrations of transforming growth factor-beta (TGF-beta). Only minimal changes were found in control samples. Pathologic scores of inflammation and fibrosis in group 1 were higher than in the vitamin E and allopurinol groups (P < 0.05). Apoptosis index was also decreased in groups 2 and 3, compared to group 1 (P < 0.05). There was no significant difference in average TGF-beta levels between study groups. These findings suggest that administration of vitamin E or allopurinol following the onset of fever can reduce renal damage in pyelonephritis.
Pediatric Urology Research Center, Department of Urology, Children's Hospital Medical Center, Tehran University/Medical Sciences, Tehran, Iran.
Zhina
Z
Sadeghi
Abdol-Mohammad
AM
Kajbafzadeh
Parvin
P
Tajik
Maryam
M
Monajemzadeh
Seyedmehdi
S
Payabvash
Azadeh
A
Elmi
D000208:Acute Disease; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002921:Cicatrix / Q000517:prevention & control*; D005334:Fever / Q000188:drug therapy*; D007668:Kidney / Q000473:pathology*; D008297:Male; D011704:Pyelonephritis / Q000150:complications* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D014810:Vitamin E / Q000627:therapeutic use*
D000975:Antioxidants; D016212:Transforming Growth Factor beta; D014810:Vitamin E